Adult Stem Cell Therapy & Regenerative Medicine
August 19th - August 21st, 2013
MSC 2013 will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. Online registration is open and poster abstracts are being accepted for presentation both in poster format and potentially accepted for platform presentation during the main program as well. Deadline is July 19, 2013 for poster abstract submission.
What does MSC stand for?
For our conference “Multipotent Stem Cell” but also Mesenchymal Stem Cell, Medicinal Signaling Cell, Mesenchymal Stromal Cell, and Marrow Stem Cell.
Who should attend?
The breadth of topics from basic discovery through model validation, clinical product development, and therapeutic application, in addition to the links between academic and commercial labs, make this conference imperative for industrial researchers, academic investigators, IP and regulatory specialists, biotechnology development investors and post-doctoral and graduate students.
Why should you attend?
- Interact with top names in the adult stem cell field – the MSC 2013 Directors, Frank Barry, Arnold Caplan, Robert Deans, Stanton Gerson, Michael Gilkey, Jan Nolta, and Mahendra Rao, chose cutting-edge researchers to be included in the program
- Present your research during the conference by submitting for a poster presentation – Podium Presentations will be chosen from submissions
- Participate in building a consensus for the next important questions in the field
- You won’t miss any of the talks, there is only one track
- Cleveland has a United Airlines hub and we negotiated a cheap room rate so your travel costs will be low
MSC 2013 will:
- Feature invited lectures from thought-leaders and provide podium talks, poster sessions, and a venue for investigators and students to present and discuss their research
- Focus on the translation of adult stem cell and tissue engineering technologies from the bench to the bedside
- Promote interactions between the research and commercialization communities to accelerate FDA approval
- Review academic and commercial cell therapy clinical trials in cardiovascular, pulmonary, neurological and immunological fields
- Include a discussion on “Standardization of MSC Nomenclature: Paracrine versus Markers” by thought leaders in the field